Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Post by Savage97on Aug 12, 2020 10:06pm
307 Views
Post# 31401294

The Wellness & Cannabis King Irwin Simon

The Wellness & Cannabis King Irwin Simon "At Aphria, we're setting ourselves apart from the rest of the cannabis industry, generating some of the strongest sales growth, maintaining one of the strongest balance sheets and cash positions, compelling consumer brands, and well-diversified global business.  Throughout the fiscal year and more recently, we further strengthened our leadership team in Leamington across core functions, for examples, in the areas of production, packaging, HR, quality, and operation. The team is doing a great job of efficiently integrating Aphria Diamond to our processes. We are consistently working to generate greater yields at lower cost. We are pleased that in Q4 cash cost per gram remained below $1 for the second straight quarter and decreased 5% from Q3 to $0.88.  We are pleased with the quick ramp-up of quality product that is coming today from Aphria Diamond. We're excited about the tremendous growth opportunities in Canada, as well as our strong medical adult-use brand sales, extraction capabilities, and our ability to export EU GMP products and white label opportunities. From enhancing our global team, our brand-building activities, new facilities, and production capabilities to investing in R&D, Aphria is well-positioned for future growth."
<< Previous
Bullboard Posts
Next >>